Novem Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$120K Hold
100
0.01% 437
2026
Q1
$92K Sell
100
-100
-50% -$101K 0.01% 426
2025
Q4
$215K Buy
200
+100
+100% +$95.6K 0.02% 392
2025
Q3
$76.3K Hold
100
0.01% 411
2025
Q2
$78K Hold
100
0.01% 398
2025
Q1
$82.6K Sell
100
-100
-50% -$83.2K 0.01% 359
2024
Q4
$154K Buy
+200
New +$166K 0.02% 357

Other funds holding LLY

Novem Group's LLY Position: Q2 2026 in Review

Novem Group reduced its Eli Lilly (LLY) stake by 2.4% in Q2 2026, selling an estimated $41.9K and leaving 1,672 shares worth $2.01M. The position accounts for 0.2% of the portfolio, ranked #101.

Novem Group first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Novem Group held 1,672 shares of Eli Lilly worth $2.01M as of Q2 2026.
  • Novem Group sold 41 Eli Lilly shares in Q2 2026, an estimated $41.9K.
  • Eli Lilly made up 0.2% of Novem Group's portfolio in Q2 2026, its #101 holding.
  • Novem Group first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Novem Group's 13F filing for Q2 2026, filed 21 Jul 2026.